HC Wainwright Predicts Higher Earnings for Alpha Cognition

Alpha Cognition Inc. (NASDAQ:ACOG – Free Report) – Research analysts at HC Wainwright boosted their FY2026 earnings per share estimates for Alpha Cognition in a research report issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($1.20) per share for the year, up from their prior estimate of ($1.27). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Alpha Cognition’s current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Alpha Cognition’s Q4 2026 earnings at ($0.23) EPS, Q1 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at $0.10 EPS and FY2027 earnings at ($0.29) EPS.

Alpha Cognition (NASDAQ:ACOG – Get Free Report) last announced its quarterly earnings data on Wednesday, November 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The company had revenue of $7.78 million during the quarter, compared to analyst estimates of $7.04 million. Alpha Cognition had a negative net margin of 147.26% and a negative return on equity of 50.90%.

Several other equities research analysts also recently weighed in on ACOG. Wall Street Zen downgraded Alpha Cognition from a “hold” rating to a “sell” rating in a report on Saturday. B. Riley Financial initiated coverage on Alpha Cognition in a research note on Thursday, August 20th. They issued a “buy” rating and a $21.00 price objective for the company. Craig Hallum reiterated a “buy” rating and issued a $17.00 price objective on shares of Alpha Cognition in a research note on Friday, August 14th. Finally, Raymond James Financial set a $21.00 price objective on Alpha Cognition and gave the stock an “outperform” rating in a research report on Thursday. Five analysts have rated the stock with a Buy rating. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $18.20.

View Our Latest Analysis on ACOG

Alpha Cognition Price Performance

ACOG opened at $7.83 on Monday. Alpha Cognition has a 12 month low of $4.50 and a 12 month high of $10.14. The business has a fifty day moving average price of $8.70 and a 200 day moving average price of $7.29.

Hedge Funds Weigh In On Alpha Cognition

A number of institutional investors and hedge funds have recently modified their holdings of ACOG. Opaleye Management Inc. increased its holdings in Alpha Cognition by 13.0% in the second quarter. Opaleye Management Inc. now owns 2,895,467 shares of the company’s stock valued at $20,905,000 after buying an additional 333,517 shares during the last quarter. AWM Investment Company Inc. acquired a new stake in Alpha Cognition in the second quarter valued at $12,073,000. Aristides Capital LLC lifted its holdings in Alpha Cognition by 1.4% during the 1st quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock worth $1,200,000 after buying an additional 3,052 shares during the last quarter. ACT Capital Partners L.P. purchased a new stake in Alpha Cognition during the 3rd quarter worth about $464,000. Finally, Marshall Wace LLP purchased a new stake in Alpha Cognition during the 3rd quarter worth about $449,000.

Insider Activity at Alpha Cognition

In other news, Director Robert Wills acquired 10,000 shares of Alpha Cognition stock in a transaction dated Friday, August 21st. The shares were acquired at an average cost of $9.62 per share, for a total transaction of $96,200.00. Following the acquisition, the director owned 32,241 shares of the company’s stock, valued at $310,158.42. This trade represents a 44.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 8.60% of the company’s stock.

About Alpha Cognition

(Get Free Report)

Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for people with neurodegenerative diseases and cognitive disorders. The company is based in Vancouver, British Columbia. Its lead product, ZUNVEYL (benzgalantamine), is an oral medication approved by the U.S. Food and Drug Administration to treat mild to moderate dementia of the Alzheimer’s type. The company developed benzgalantamine as a prodrug of galantamine. Alpha Cognition is also developing ALPHA-1062 for potential use in other cognitive disorders, including cognitive impairment associated with traumatic brain injury.

Featured Articles

Earnings History and Estimates for Alpha Cognition (NASDAQ:ACOG)

Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.